Search Result

Isoforms Recommended:	Na_v1.7

Results for "

NaV1.7

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Apoptosis (1) Calcium Channel (1) Cytochrome P450 (1) Interleukin Related (1) Melatonin Receptor (1) NF-κB (1) P2X Receptor (1) p38 MAPK (1) Potassium Channel (2) Sodium Channel (71) TNF Receptor (1) TRP Channel (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (3) Inflammation/Immunology (11) Neurological Disease (69)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13985

Nav1.7 inhibitor	Sodium Channel	Neurological Disease
Nav1.7 inhibitor (compound II), a sulfonamide, is a potent *Nav1.7* inhibitor. Nav1.7 inhibitor has the potential for a wide range of disorders, particularly pain .

HY-119934

NaV1.7 inhibitor-1	Sodium Channel	Neurological Disease
NaV1.7 inhibitor-1 is an efficacious voltage-gated sodium channel (NaV) 1.7 inhibitor with an IC₅₀ of 0.6 nM for hNaV1.7, exhibits 80-fold selectivity versus hNaV1.5 .

HY-101789

Nav1.7-IN-3	Sodium Channel	Neurological Disease
Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC₅₀ of 8 nM. Pain relief. Limited CNS penetration .

HY-19366

Nav1.7-IN-2	Sodium Channel	Neurological Disease
Nav1.7-IN-2 is an inhibitor of voltage-gated sodium channels (Nav), in particular Nav 1.7, with IC50 of 80 nM.

HY-116194

NaV1.7 blocker-801	Sodium Channel	Neurological Disease
NaV1.7 blocker-801 is a NaV1.7 channel blocker that can be used in the study of neurological diseases .

HY-160663

Nav1.7 blocker 1	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.7 blocker 1 (example 41) is a Na ⁺ channel (Na_v) blocker with an IC₅₀ value of 0.037 μM. Nav1.7 blocker 1 can be used for the study of pain, including neuropathic pain, postoperative pain, inflammatory pain, and so on .

HY-141547

Nav1.7-IN-8	Sodium Channel Cytochrome P450	Inflammation/Immunology
Nav1.7-IN-8 is a potent blockage of *NaV1.7* with high selectivity for the inhibition of *NaV1.7* over the subtypes hNaV1.1 and hNaV1.5. Nav1.7-IN-8 inhibits CYP2C9 and CYP3A4 with an IC₅₀ of 0.17 μM and 0.077 μM, respectively. Nav1.7-IN-8 displays significant analgesic effects in rodent models of acute and inflammatory pain .

HY-102998

Nav1.7-IN-6	Sodium Channel	Neurological Disease
Nav1.7-IN-6 (example 346) is a *Nav1.7* selective inhibitor, which is extracted from patent WO2015078374A1 .

HY-138816

Nav1.7-IN-15	Sodium Channel	Neurological Disease
Nav1.7-IN-15 (Compd 9) is a potent and state-dependent *Nav1.7* antagonist, with an IC₅₀ of 0.42 μM for hNav1.7 PX .

HY-162347

Nav1.7-IN-13	Sodium Channel	Neurological Disease
Nav1.7-IN-13 (compound 3g) is a sodium channel inhibitor that significantly inhibits Veratridine (HY-N6691)-induced neuronal activity. Nav1.7-IN-13 inhibits total Na+ current in DRG neurons in a concentration-dependent manner; slows down the activation of Navs. Nav1.7-IN-13 significantly alleviated mechanical pain behavior in a rat model of nerve injury (SNI) and had analgesic activity .

HY-116137

Nav1.7-IN-17	Others	Others
Nav1.7-IN-17 is an active compound.

HY-139081

GDC-0310	Sodium Channel	Neurological Disease
GDC-0310 is a selective acyl-sulfonamide *Na_v1.7* inhibitor, with an IC₅₀ of 0.6 nM for hNa_v1.7 .

HY-131870

GX-201	Sodium Channel	Inflammation/Immunology
GX-201 is a selective *Na_V1.7* inhibitor, with an IC₅₀ of <3.2 nM for hNa_V1.7 .

HY-118952

PF-06456384	Sodium Channel	Neurological Disease
PF-06456384 is a highly potent and selective *Na_V1.7* inhibitor with an IC₅₀ of 0.01 nM. PF-06456384 has the potential for formalin pain model research .

HY-118952A

PF-06456384 trihydrochloride	Sodium Channel	Neurological Disease
PF-06456384 trihydrochloride is a highly potent and selective *Na_V1.7* inhibitor with an IC₅₀ of 0.01 nM. PF-06456384 trihydrochloride has the potential for formalin pain model research .

HY-12883A

PF-05198007	Sodium Channel	Neurological Disease
PF-05198007 is a potent, orally active and selective arylsulfonamide *Na_v1.7* inhibitor. PF-05198007 is a compound with a similar pharmacodynamic profile to PF-05089771 .

HY-162609

ST-2560	Sodium Channel	Cardiovascular Disease Neurological Disease
ST-2560 is a selective inhibitor of the *NaV1.7* sodium channel with IC₅₀ value of 39 nM. ST-2560 can be used to study pain behavior and cardiovascular models .

HY-16723A

(R)-Funapide (R)-TV 45070; (R)-XEN402	Sodium Channel	Neurological Disease Inflammation/Immunology
(R)-Funapide ((R)-TV 45070) is the less active R-enantiomer of Funapide. Funapide is a potent inhibitor of the sodium channel *Nav1.7, Nav1.8* and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent .

HY-122001

PF-05186462	Sodium Channel	Neurological Disease
PF-05186462 is a potent and selective inhibitor of *human Nav1.7* voltage-dependent sodium channel, with an IC₅₀** of 21 nM. PF-05186462 shows significant selectivity for Nav1.7 versus other sodium channels (Nav 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, and 1.8). PF-05186462 can be used for the research of acute or chronic pain .

HY-19958

XEN907	Sodium Channel	Neurological Disease
XEN907 is a potent and spirooxindole blocker of *Na_V1.7, with an IC₅₀* of 3 nM. XEN907 also inhibits CYP3A4 in a recombinant human enzyme assay. XEN907 can be used for the research of pain .

HY-16723

Funapide TV 45070; XEN402	Sodium Channel	Neurological Disease Inflammation/Immunology
Funapide (TV 45070; XEN402) is a potent inhibitor of the sodium channel *Nav1.7, Nav1.8* and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent .

HY-117714

AZD-3161	Sodium Channel	Neurological Disease
AZD-3161 is a potent and selective blocker of Na_V1.7 channel, with a pIC₅₀ of 7.1. AZD-3161 can be used for the research of neuropathic and inflammatory pain .

HY-146069

ABBV-318	Sodium Channel	Neurological Disease
ABBV-318 is a potent **Nav1.7/ Nav1.8 blocker, with IC₅₀s of 2.8 μM and 3.8 μM for hNav1.7 and hNav1.8**, respectively. ABBV-318 can be used for the research of pain .

HY-103623

PF-05241328	Sodium Channel	Neurological Disease
PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels *(Nav1.7), with an IC₅₀* of 31 nM.

HY-100727

AM-2099	Sodium Channel	Neurological Disease
AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel *Nav1.7* with an IC₅₀ of 0.16 μM for human Nav1.7.

HY-P5801

Phlo1a μ-TrTx-Phlo1a	Sodium Channel	Neurological Disease
Phlo1a (μ-TrTx-Phlo1a) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1a has a weak inhibitory effect on Nav1.2 and Nav1.5 .

HY-P1220

Huwentoxin-IV	Sodium Channel	Neurological Disease
Huwentoxin-IV is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P1220A

Huwentoxin-IV TFA	Sodium Channel	Neurological Disease
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P5800

Phlo1b μ-TrTx-Phlo1b	Sodium Channel	Neurological Disease
Phlo1b (μ-TrTx-Phlo1b) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1b has a weak inhibitory effect on Nav1.2 and Nav1.5 .

HY-12811

PF-04856264	Sodium Channel	Neurological Disease
PF-04856264 is a potent and selective *Nav1.7* inhibitor, with IC₅₀s of 28, 131, 19, and 42 nM for human, mouse, cynomolgus monkey and dog Nav1.7, respectively. PF-04856264 has low potency against the rat Nav1.7 channel. PF-04856264 shows analgesic effect .

HY-P5786

Heteropodatoxin-1	Potassium Channel Sodium Channel	Neurological Disease
Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits *Nav1.7* and activates *Nav1.9* but does not affect Nav1.8 .

HY-123833

PF-05661014	Sodium Channel	Others
PF-05661014, a desmethyl analogue of PF-06526290, selectively inhibits Nav1.3 and Nav1.7 currents by stabilizing inactivated channels via interaction with D4 VSD. PF-05661014 can be used for research of sodium channel modulation .

HY-N6691

Veratridine 3 Publications Verification 3-Veratroylveracevine	Sodium Channel	Neurological Disease
Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC₅₀ of 18.39 µM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow .

HY-149994

DS43260857	Sodium Channel	Neurological Disease
DS43260857 is a potentNaV1.7inhibitor, which has a high inhibitory effect on both human and mouse NaV1.7. The IC₅₀ values of DS43260857 for hNaV1.1, hNaV1.5, hNaV1.7, mNaV1.7 are 6.6, 14, 0.015 and 0.061 μM, respectively .

HY-P1681

GpTx-1	Sodium Channel	Neurological Disease
GpTx-1 is a potent and selective *Na_V1.7* antagonist with an IC₅₀ of 10 nM .

HY-112279

GNE-131	Sodium Channel	Neurological Disease
GNE-131 is a potent and selective inhibitor of human sodium channel *NaV1.7, with an IC₅₀* of 3 nM.

HY-P1221A

ProTx II TFA	Sodium Channel	Neurological Disease
ProTx II TFA is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-P1221

ProTx II	Sodium Channel	Neurological Disease
ProTx II is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-145169

AZ194	Sodium Channel	Neurological Disease
AZ194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of *NaV1.7* (IC₅₀=1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects .

HY-N6691R

Veratridine (Standard)	Sodium Channel	Neurological Disease
Veratridine (Standard) is the analytical standard of Veratridine. This product is intended for research and analytical applications. Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC₅₀ of 18.39?μM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow .

HY-12796

Raxatrigine Vixotrigine; GSK-1014802; CNV1014802	Sodium Channel	Neurological Disease
Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.

HY-12796A

Raxatrigine hydrochloride Vixotrigine hydrochloride; GSK-1014802 hydrochloride; CNV1014802 hydrochloride	Sodium Channel	Neurological Disease
Raxatrigine hydrochloride (GSK-1014802 hydrochloride) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.

HY-167852

GX-585	Others	Neurological Disease Inflammation/Immunology
GX-585 is a sulfonamide analog that acts as a Nav1.7 channel inhibitor, demonstrating analgesic activity in treating neuropathic pain and inflammation.

HY-P5809

Pe1b μ-TrTx-Pe1b	Sodium Channel	Neurological Disease
Pe1b (μ-TrTx-Pe1b) is a selective *Na_v1.7* inhibitor with an IC₅₀ of 167 nM .

HY-155236

Ancistrotecine B	Sodium Channel	Inflammation/Immunology
Ancistrotecine B (Compound 2) is a *Nav1.7* channel inhibitor (IC₅₀: 0.73 μM). Ancistrotecine B relieves inflammatory pain in mice .

HY-128794

PF-05150122	Others	Neurological Disease
PF-05150122 is a novel potent and selective human Nav1.7 channel blocker with the activity of inhibiting human pain signaling. PF-05150122 exhibited favorable biopharmacokinetic parameters in microdose studies, providing a basis for exploring its application in acute or chronic pain inhibition. The pharmacokinetic model of PF-05150122 predicted that at the corresponding oral dose, it could effectively reduce the 50% inhibitory concentration (IC50) of Nav1.7, demonstrating its inhibitory potential .

HY-123825

GX-674	Sodium Channel	Cardiovascular Disease Neurological Disease
GX-674 is a potent, state-dependent, isoform-selective voltage-gated sodium channel 1.7 (Nav1.7) antagonist with an IC₅₀ of 0.1 nM at -40 mV .

HY-118048

NAV 26	Sodium Channel	Neurological Disease
NAV 26 (compound 26) is a selective voltage-gated sodium channel Nav1.7 blocker with an IC₅₀ of 0.37 μM. NAV 26 can be used for pain research .

HY-P1443

OD1	Sodium Channel	Cancer
OD1 is a scorpion α-toxin that can be isolated from the venom of the Iranian yellow scorpion (Odonthobuthus doriae. OD1 is a modulator of mammalian *Nav1.7* (EC₅₀: 4.5 nM) .

HY-P5793

GTx1-15	Sodium Channel Calcium Channel	Neurological Disease
GTx1-15 is an inhibitor cystine knot (ICK) peptide that inhibits the voltage-dependent calcium channel Cav3.1 and the voltage-dependent sodium channels Nav1.3 and *Nav1.7* .

Cat. No.	Product Name	Target	Research Area

HY-P1220A

Huwentoxin-IV TFA	Sodium Channel	Neurological Disease
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P1221A

ProTx II TFA	Sodium Channel	Neurological Disease
ProTx II TFA is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-P5801

Phlo1a μ-TrTx-Phlo1a	Sodium Channel	Neurological Disease
Phlo1a (μ-TrTx-Phlo1a) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1a has a weak inhibitory effect on Nav1.2 and Nav1.5 .

HY-P1220

Huwentoxin-IV	Sodium Channel	Neurological Disease
Huwentoxin-IV is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P5800

Phlo1b μ-TrTx-Phlo1b	Sodium Channel	Neurological Disease
Phlo1b (μ-TrTx-Phlo1b) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1b has a weak inhibitory effect on Nav1.2 and Nav1.5 .

HY-P5786

Heteropodatoxin-1	Potassium Channel Sodium Channel	Neurological Disease
Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits *Nav1.7* and activates *Nav1.9* but does not affect Nav1.8 .

HY-P1681

GpTx-1	Sodium Channel	Neurological Disease
GpTx-1 is a potent and selective *Na_V1.7* antagonist with an IC₅₀ of 10 nM .

HY-P1221

ProTx II	Sodium Channel	Neurological Disease
ProTx II is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-P5809

Pe1b μ-TrTx-Pe1b	Sodium Channel	Neurological Disease
Pe1b (μ-TrTx-Pe1b) is a selective *Na_v1.7* inhibitor with an IC₅₀ of 167 nM .

HY-P1443

OD1	Sodium Channel	Cancer
OD1 is a scorpion α-toxin that can be isolated from the venom of the Iranian yellow scorpion (Odonthobuthus doriae. OD1 is a modulator of mammalian *Nav1.7* (EC₅₀: 4.5 nM) .

HY-P5793

GTx1-15	Sodium Channel Calcium Channel	Neurological Disease
GTx1-15 is an inhibitor cystine knot (ICK) peptide that inhibits the voltage-dependent calcium channel Cav3.1 and the voltage-dependent sodium channels Nav1.3 and *Nav1.7* .

HY-P5865

Tap1a Theraphotoxin-Tap1a; TRTX-Tap1a; µ/ω-TRTX-Tap1a	Sodium Channel	Neurological Disease
Tap1a (Theraphotoxin-Tap1a) is a spider venom peptide that inhibits sodium channels with IC₅₀s of 80 nM and 301 nM against Na_v1.7 and Na_v1.1, respectively. Tap1a shows analgesic effects .

HY-P5160

Phlotoxin-1 PhlTx1	Sodium Channel	Inflammation/Immunology
Phlotoxin-1 (PhlTx1) is a 34-amino acid and 3-disulfide bridge peptide. Phlotoxin-1 can be isolated from Phlogiellus genus spider. Phlotoxin-1 is an antinociceptive agent by inhibiting *NaV1.7* channel .

HY-P5781

δ-Theraphotoxin-Hm1b	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1b is a 42-amino acid peptide isolated from Togo starburst tarantula (Heteroscodra maculata) venom. δ-Theraphotoxin-Hm1b selectively inhibits inactivation of *NaV1.1* but have no effect on NaV1.7 .

HY-P5813

Cd1a β-TRTX-cd1a; β-Theraphotoxin-cd1a	Peptides	Neurological Disease
Cd1a is a β-toxin derived from the African spider Ceratogyrus darlingi. Cd1a can regulate calcium ion channels. Cd1a inhibits human calcium ion channels (Ca_v2.2)(IC₅₀2.6 μM) and mouse sodium ion channels (Na_v1.7). Cd1a can be used in the development of peripheral pain treatment drugs .

HY-P5153

ProTx-III μ-TRTX-Tp1a	Sodium Channel	Neurological Disease
ProTx-III is a selective and potent inhibitor of voltage-gated sodium channel *Na_v1.7, with an IC₅₀* of 2.1 nM. ProTx-III is a spider venom peptide isolated from the venom of the Peruvian green velvet tarantella. ProTx-III has a typical inhibitor cystine knot motif (ICK). ProTx-III is able to reverse the pain response. ProTx-III can be used to study diseases such as chronic pain, epilepsy, and arrhythmia .

HY-P5795

GsAF-I	Sodium Channel Potassium Channel	Neurological Disease
GsAF-I is a potent *Na_v* and hERG1 channels blocker with IC₅₀s of 0.36, 0.6, 1.28, 0.33, 1.2, 0.04 and 4.8 μM against Na_v1.1, Na_v1.2, Na_v1.3, Na_v1.4, Na_v1.6, Na_v1.7 and hERG1, respectively .

HY-P5164

GrTx1	Sodium Channel	Neurological Disease
GrTx1 is a peptide toxin originally isolated from the venom of the spider Grammostola rosea. GrTx1 blocks sodium channel， with IC₅₀s of 0.63 µM, 0.23 µM, 0.77 µM, 1.29 µM, 0.63 µM and 0.37 µM for Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.6 and Nav1.7, repectively .GrTx1 can be used for neurological disease research .

HY-P5900

m3-Huwentoxin IV m3-HwTx-IV	Sodium Channel	Neurological Disease
m3-Huwentoxin IV (m3-HwTx-IV) is a potent *Na_V* inhibitor with IC₅₀s of 3.3, 6.8, 7.2, 8.4, 11.9 and 369 nM against hNa_V1.7, hNa_V1.6, hNa_V1.3, hNa_V1.1, hNa_V1.2 and hNa_V1.4, respectively in QPatch assay. m3-Huwentoxin IV dose-dependently suppresses spontaneous pain induced by the Na_V1.7 activator OD1 in a rodent pain model .

HY-P5790

μ-TRTX-Hd1a	Sodium Channel	Neurological Disease
μ-TRTX-Hd1a, a spider venom, is a selective *NaV 1.7* inhibitor. μ-TRTX-Hd1a is a gating modifier that inhibits human NaV 1.7 by interacting with the S3b-S4 paddle motif in channel domain II .

Cat. No.	Product Name	Target	Research Area

HY-P990503

*Anti-SCN9a/Nav1.7* Antibody**	Inhibitory Antibodies	Inflammation/Immunology
Anti-SCN9a/Nav1.7 Antibody is a human antibody expressed in CHO, targeting *SCN9a/Nav1.7. Anti-SCN9a/Nav1.7* Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Cat. No.	Compare	Product Name	Species	Source

HY-P703462

	*VSD4-NaV1.7-NaVPas Protein, Human (HEK293, Flag, Strep)* NENA	Human	HEK293
	VSD4-NaV1.7-NaVPas Protein, Human (HEK293, Flag, Strep) is the recombinant human-derived VSD4-NaV1.7-NaVPas, expressed by HEK293 , with Strep, Flag labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

NaV1.7

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Natural
Products